Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 9.66 is 31% above its 5-year average of 7.38, around the middle of its 5-year range (1.92–13.78).
As of the fiscal period ended Tuesday, June 30, 2026. 5.35% above its 12-month average of 9.17.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 9.66.
CURRENT RATIO
9.66
CURRENT RATIO AVG TTM
9.17
CURRENT RATIO AVG 3Y
6.86
CURRENT RATIO AVG 5Y
7.38
CURRENT RATIO AVG 10Y
11.18
CURRENT RATIO AVG 15Y
9.94
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+5.35%
CURRENT VS 3Y AVG
+40.81%
CURRENT VS 5Y AVG
+30.81%
CURRENT VS 10Y AVG
-13.65%
CURRENT VS 15Y AVG
-2.83%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.34
median of 522 covered companies
CURRENT VS SECTOR MEDIAN
+188.69%
vs the sector median at left
Crescent Biopharma, Inc.
Market Cap
$534.87M
Current Ratio
9.66
TTM Avg
9.17
3Y Avg
6.86
5Y Avg
7.38
Market Cap
$541.30M
Current Ratio
25.13
TTM Avg
6.17
3Y Avg
7.34
5Y Avg
19.91
Market Cap
$514.28M
Current Ratio
10.72
TTM Avg
8.23
3Y Avg
9.67
5Y Avg
9.58
Market Cap
$557.32M
Current Ratio
9.36
TTM Avg
2.17
3Y Avg
1.76
5Y Avg
2.63
Market Cap
$568.83M
Current Ratio
5.42
TTM Avg
12.18
3Y Avg
12.18
5Y Avg
12.18
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Crescent Biopharma, Inc. (CBIO) | $534.87M | 9.66 | 9.17 | 6.86 | 7.38 |
| Immix Biopharma, Inc. (IMMX)vs › | $541.30M | 25.13 | 6.17 | 7.34 | 19.91 |
| Altimmune, Inc. (ALT)vs › | $521.19M | 26.78 | 15.83 | 15.06 | 15.09 |
| Delcath Systems, Inc. (DCTH)vs › | $548.86M | 9.83 | 11.46 | 6.57 | 5.79 |
| Allogene Therapeutics, Inc. (ALLO)vs › | $514.28M | 10.72 | 8.23 | 9.67 | 9.58 |
| NeoGenomics, Inc. (NEO)vs › | $514.16M | 3.60 | 3.12 | 4.79 | 5.52 |
| CytomX Therapeutics, Inc. (CTMX)vs › | $557.32M | 9.36 | 2.17 | 1.76 | 2.63 |
| CorMedix Inc. (CRMD)vs › | $566.22M | 2.56 | 2.75 | 5.48 | 7.66 |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $568.83M | 5.42 | 12.18 | 12.18 | 12.18 |
| Aquestive Therapeutics, Inc. (AQST)vs › | $570.25M | 7.19 | 3.91 | 2.77 | 2.56 |
Current Ratio
9.66
Quick Ratio
9.66
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 9.66 |
| 2026-03-31 | 13.78 |
| 2025-12-31 | 6.56 |
| 2025-09-30 | 6.63 |
| 2025-06-30 | 9.21 |
| 2025-03-31 | 2.29 |
| 2024-12-31 | 1.92 |
| 2024-09-30 | 3.62 |
| 2024-06-30 | 5.48 |
| 2024-03-31 | 6.28 |
| 2023-12-31 | 6.41 |
| 2023-09-30 | 8.14 |
| 2023-06-30 | 9.19 |
| 2023-03-31 | 10.10 |
| 2022-12-31 | 5.71 |
| 2022-09-30 | 6.95 |
| 2022-06-30 | 6.85 |
| 2022-03-31 | 6.06 |
| 2021-12-31 | 7.68 |
| 2021-09-30 | 10.78 |
| 2021-06-30 | 11.74 |
| 2021-03-31 | 12.33 |
| 2020-12-31 | 11.13 |
| 2020-09-30 | 14.83 |
| 2020-06-30 | 15.81 |
| 2020-03-31 | 14.78 |
| 2019-12-31 | 14.84 |
| 2019-09-30 | 16.75 |
| 2019-06-30 | 17.54 |
| 2019-03-31 | 23.88 |
| 2018-12-31 | 24.22 |
| 2018-09-30 | 34.57 |
| 2018-06-30 | 33.10 |
| 2018-03-31 | 28.30 |
| 2017-12-31 | 15.56 |
| 2017-09-30 | 17.44 |
| 2017-06-30 | 21.97 |
| 2017-03-31 | 7.78 |
| 2016-12-31 | 6.40 |
| 2016-09-30 | 8.59 |
| 2016-06-30 | 8.95 |
| 2016-03-31 | 6.95 |
| 2015-12-31 | 6.10 |
| 2015-09-30 | 7.95 |
| 2015-06-30 | 8.94 |
| 2015-03-31 | 11.54 |
| 2014-12-31 | 8.69 |
| 2014-09-30 | 13.14 |
| 2014-06-30 | 18.65 |
| 2014-03-31 | 21.83 |
| 2013-12-31 | 2.14 |
| 2013-09-30 | 3.13 |
| 2013-06-30 | 6.68 |
| 2013-03-31 | 0.00 |
| 2012-12-31 | 3.16 |
| 2012-09-30 | 0.00 |
